| Literature DB >> 33139735 |
Chenjie Wan1,2, Nadine Bachmann1,3, Venelin Mitov4,5, François Blanquart6, Susana Posada Céspedes5,7, Teja Turk1,3, Kathrin Neumann1,3, Niko Beerenwinkel7, Jasmina Bogojeska8, Jacques Fellay9,10, Volker Roth11, Jürg Böni3, Matthieu Perreau12, Thomas Klimkait13, Sabine Yerly14, Manuel Battegay15, Laura Walti16, Alexandra Calmy17, Pietro Vernazza18, Enos Bernasconi19, Matthias Cavassini20, Karin J Metzner1,3, Huldrych F Günthard1,3, Roger D Kouyos21,22.
Abstract
The HIV-1 reservoir is the major hurdle to curing HIV-1. However, the impact of the viral genome on the HIV-1 reservoir, i.e. its heritability, remains unknown. We investigate the heritability of the HIV-1 reservoir size and its long-term decay by analyzing the distribution of those traits on viral phylogenies from both partial-pol and viral near full-length genome sequences. We use a unique nationwide cohort of 610 well-characterized HIV-1 subtype-B infected individuals on suppressive ART for a median of 5.4 years. We find that a moderate but significant fraction of the HIV-1 reservoir size 1.5 years after the initiation of ART is explained by genetic factors. At the same time, we find more tentative evidence for the heritability of the long-term HIV-1 reservoir decay. Our findings indicate that viral genetic factors contribute to the HIV-1 reservoir size and hence the infecting HIV-1 strain may affect individual patients' hurdle towards a cure.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33139735 PMCID: PMC7608612 DOI: 10.1038/s41467-020-19198-7
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Patient characteristics.
| Population A | Population B | ||
|---|---|---|---|
| Sequenced HIV-1 genomic region | Near full-length | Partial | |
| 351 | 610 | ||
| Age at first HIV-1 DNA sample, in years (median [IQR]) | 42 [37,48] | 43 [37,48] | |
| Ethnicity (%) | White | 333 (94.87) | 566 (92.79) |
| Non-white | 18 (5.13) | 44 (7.21) | |
| Sex (%) | Male | 307 (87.46) | 532 (87.21) |
| Female | 44 (12.54) | 78 (12.79) | |
| Transmission group by sex (%) | MSM | 247 (70.37) | 403 (66.07) |
| HET male | 33 (9.4) | 76 (12.46) | |
| HET female | 31 (8.83) | 50 (8.2) | |
| PWID male | 22 (6.27) | 37 (6.07) | |
| PWID female | 8 (2.28) | 20 (3.28) | |
| Other male | 6 (1.71) | 17 (2.79) | |
| Other female | 4 (1.14) | 7 (1.15) | |
| Time of untreated HIV-1 infection, in years (%) | <1 | 43 (12.25) | 100 (16.39) |
| 1–3 | 51 (14.53) | 82 (13.44) | |
| 3–5 | 90 (25.64) | 150 (24.59) | |
| 5–7 | 61 (17.38) | 104 (17.05) | |
| >7 | 106 (30.2) | 174 (28.52) | |
| Time on ART at first HIV-1 DNA sample, in years (median [IQR]) | 1.5 [1.3,1.7] | 1.5 [1.3–1.7] | |
| Time from ART initiation to below <50 HIV-1 RNA copies/ml, in years (median [IQR]) | 0.3 [0.2,0.5] | 0.3 [0.2,0.5] | |
| CD4+ cell count pre-ART/μl blood (median [IQR]) | 215 [130, 286] | 214 [123, 299] | |
| log 10 HIV-1 plasma RNA pre-ART/ml plasma (median [IQR]) | 5.0 [4.5, 5.4] | 4.9 [4.4,5.4] | |
| HIV-1 RNA (180 days after ART initiation - 1st HIV-1 DNA sample) (%) | <50 copies/ml | 273 (77.78) | 472 (77.38) |
| Viral blips | 48 (13.68) | 82 (13.44) | |
| Low level viremia | 27 (7.69) | 53 (8.69) | |
| HIV-1 RNA (1st - 3rd HIV-1 DNA sample) (%) | <50 copies/ml | 232 (66.1) | 407 (66.72) |
| Viral blips | 88 (25.07) | 154 (25.25) | |
| Low level viremia | 31 (8.83) | 49 (8.03) | |
Patient characteristics in population A (with available viral near full-length NGS sequences obtained from HIV-1 plasma RNA) and population B (with available partial pol Sanger sequences obtained from HIV-1 plasma RNA).
The time of untreated HIV-1 infection was calculated using the estimated HIV-1 infection dates. Pre-ART log10 HIV-1 RNA copies/ml plasma and pre-ART CD4+ cell count/μl blood refer to the last laboratory values available before initiation of ART. Transmission group stratified by sex indicates the self-reported route of infection (men who have sex with men (MSM), heterosexual (HET), people who inject drugs (PWID), and other (including unknown, transfusions, and perinatal transmission)).
Fig. 1Patient inclusion flowchart.
ART antiretroviral therapy, PBMC peripheral blood mononuclear cells.
Fig. 2Heritability estimates for HIV-1 reservoir size based on the phylogenies built from near full-length HIV-1 genome NGS sequences and partial pol Sanger sequences.
OU: Ornstein Uhlenbeck model. BM: Brownian motion model. ME: Mixed-effect model with corresponding phylogenetic distance threshold (substitutions per site). N: Number of patients included in the analysis. Patients with incomplete information of potential covariables were excluded. For BM and OU, all eligible patients from the tree were included while for mixed-effect model, only patients in the extracted transmission clusters were included. Black dots and black confidence intervals show the heritability estimates adjusted for covariables while blue rectangles and gray confidence intervals show the unadjusted estimates. 95% confidence intervals are shown in square brackets.
Fig. 3Heritability estimates for HIV-1 reservoir decay slope based on phylogenies built from near full-length HIV-1 genome NGS sequences and partial pol Sanger sequences.
OU: Ornstein Uhlenbeck model. BM: Brownian motion model. ME: Mixed-effect model with corresponding phylogenetic distance threshold (substitutions per site). N: Number of patients included in the analysis. Patients with incomplete information of potential covariables were excluded. For BM and OU, all eligible patients from the tree were included while for mixed-effect model, only patients in the extracted transmission clusters were included. Black dots and black confidence intervals show the heritability estimates adjusted for covariables while blue rectangles and gray confidence intervals show the unadjusted estimates. 95% confidence intervals are shown in square brackets.